APR 10, 2019 12:00 PM PDT

Best Practices for Implementing NGS and Positioning for Future Growth: Perspectives from 2 Labs

SPONSORED BY: Illumina
C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Executive Director of the Advanced Diagnostic Laboratories, Moffitt Cancer Center
    Biography
      Dr. Magliocco has over 25 years experience as a Professor, Researcher, Pathologist, Laboratory Director, Consultant, Tissue Banker, and public speaker. He is Board Certified in Anatomic Pathology and has extensive experience and sub-specialty expertise in Breast, Gyn, and Molecular Pathology. He has held continuous peer reviewed funding in translational research and his laboratory is currently investigating the mechanisms of ovarian cancer metastasis and treatment evasion. He has founded numerous molecular diagnostic laboratories in the USA and Canada, has published over 200 manuscripts in oncology, and holds numerous diagnostic technology patents. He is currently Executive Director of Esoteric Laboratory Services at the Moffitt Cancer, as well as Scientific Director for Moffitt Tissue Core, one of the largest bio banking programs in the world. He also directs the newly formed Moffitt Morsani Advanced Diagnostics Laboratories which is focused on accelerating development of new CLIA laboratory diagnostics. Dr Magliocco also directs fellowship programs in Molecular Diagnostics and Digital Pathology. He has held numerous national and international roles including Chair of Pathology for the Radiation Therapy and Oncology Clinical Trials group, member of the NCI GU steering committee, and member of the Canadian Cancer Clinical Trials Network Steering committee, as well as previous editorial position with the Journal of Surgical Oncology and is frequent reviewer for numerous other Oncology and Pathology Journals.
    • Laboratory Operations Director, Navican Precision Cancer Care
      Biography
        Keith Gligorich, PhD, is the Laboratory Operations Director at NAVICAN Precision Cancer Care, an Intermountain Healthcare Company. NAVICAN provides TheraMap™, an end-to-end solution helping oncologists and patients harness the power of precision genomics, clinical analytics, and patient services for optimal cancer management. Prior to joining NAVICAN, Dr. Gligorich was a Research Assistant Professor in the Department of Pathology at the University of Utah and a Lead Scientist at ARUP Laboratories. In this role, he led a team of scientists focused on developing solid tumor molecular and NGS diagnostic tests. Dr. Gligorich earned a PhD in Chemistry from the University of Utah. He continued his training as a Department of Defense Breast Cancer Research Program Post-Doctoral Fellow at the Huntsman Cancer Institute.

      Abstract:

      Personalized medicine driven by genomic-based treatments continues to increase in importance. Representatives from two distinct healthcare entities – a regional reference lab and community based cancer medical center – provided their perspectives on how they approach the challenge of addressing this need. The speakers will present on the reasons why they chose to internalize NGS testing, the value it brings to their healthcare system/network and what was involved to actualize their programs. Digital analytics and analysis employed by LTS Health was incorporated to provide feedback on the impact to laboratory operations and forecasting for future growth.  

      Learning Objectives: 

      1. Recognize the biomarkers that prompt the need for a multi-gene panel to maximize testing results from a single tissue biopsy. 
      2. List the attributes of a Comprehensive Genomics Panel that would be used to drive personalized medicine testing using NGS (next-generation sequencing). 
      3. Describe the Molecular Tumor Board considerations when doing case reviews. 
      4. Identify the components of a Quality Management System for NGS (next-generation sequencing) workflows. 


      Show Resources
      You May Also Like
      JUN 05, 2019 05:00 PM CEST
      C.E. CREDITS
      JUN 05, 2019 05:00 PM CEST
      DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
      SEP 05, 2019 04:00 PM CEST
      C.E. CREDITS
      SEP 05, 2019 04:00 PM CEST
      DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
      AUG 27, 2019 09:00 AM PDT
      C.E. CREDITS
      AUG 27, 2019 09:00 AM PDT
      DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
      OCT 02, 2019 11:00 AM PDT
      OCT 02, 2019 11:00 AM PDT
      DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
      JUN 26, 2019 09:00 AM PDT
      C.E. CREDITS
      JUN 26, 2019 09:00 AM PDT
      DATE: June 26, 2019TIME: 9:00am PDT, 12:00pm EDT An excessive number of software solutions are available to help manage your clinical, biobank, or biorepository sample inform...
      JUL 30, 2019 10:00 AM PDT
      C.E. CREDITS
      JUL 30, 2019 10:00 AM PDT
      DATE: July 30, 2019TIME: 10:00am PT/ 1:00pm ET The importance of building a validation structure within your lab cannot be overstated. Once in place, the ability to identify high...
      Loading Comments...
      Show Resources